Hennion & Walsh Asset Management Inc. Purchases 206,543 Shares of Zevra Therapeutics, Inc. $ZVRA

Hennion & Walsh Asset Management Inc. boosted its position in shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) by 116.6% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 383,706 shares of the company’s stock after acquiring an additional 206,543 shares during the period. Hennion & Walsh Asset Management Inc.’s holdings in Zevra Therapeutics were worth $5,502,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. ProShare Advisors LLC grew its holdings in Zevra Therapeutics by 12.3% in the fourth quarter. ProShare Advisors LLC now owns 12,669 shares of the company’s stock worth $114,000 after purchasing an additional 1,390 shares during the last quarter. The Manufacturers Life Insurance Company increased its position in shares of Zevra Therapeutics by 9.4% during the second quarter. The Manufacturers Life Insurance Company now owns 20,294 shares of the company’s stock worth $179,000 after purchasing an additional 1,750 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of Zevra Therapeutics by 6.1% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 31,761 shares of the company’s stock valued at $238,000 after purchasing an additional 1,812 shares during the last quarter. Deutsche Bank AG lifted its holdings in shares of Zevra Therapeutics by 4.4% during the 4th quarter. Deutsche Bank AG now owns 45,939 shares of the company’s stock valued at $412,000 after purchasing an additional 1,936 shares during the last quarter. Finally, MetLife Investment Management LLC boosted its position in shares of Zevra Therapeutics by 10.5% in the 4th quarter. MetLife Investment Management LLC now owns 27,867 shares of the company’s stock worth $250,000 after purchasing an additional 2,653 shares in the last quarter. 35.03% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Zevra Therapeutics

Here are the key news stories impacting Zevra Therapeutics this week:

• Positive Sentiment: Q2 earnings and revenue exceeded expectations. Zevra reported quarterly EPS of $0.25 versus the $0.11 consensus estimate, while revenue reached $39.66 million, above expectations of $33.88 million. The company also posted a 42.82% net margin and positive operating cash flow. Zevra Therapeutics quarterly earnings report
• Positive Sentiment: Analysts remain bullish. Citizens raised its price target from $25 to $28 and assigned a “market outperform” rating. HC Wainwright maintained a “Buy” rating and a $26 target, while increasing its FY2026 EPS forecast to $0.57 from $0.55. Citizens price-target update
• Positive Sentiment: Regulatory and intellectual-property developments could improve MIPLYFFA’s long-term outlook. Zevra outlined a timeline for a CHMP reexamination opinion expected in the fourth quarter, while its MIPLYFFA Orange Book listing reportedly extends to 2041. Zevra CHMP and Orange Book update
• Neutral Sentiment: Guggenheim trimmed its price target to $23 from $24 but retained a “Buy” rating, leaving a target substantially above the current trading level. Guggenheim price-target update
• Negative Sentiment: HC Wainwright reduced its Q4 2026 EPS forecast to $0.13 from $0.17, signaling weaker near-term earnings expectations despite raising its full-year forecast.
• Negative Sentiment: Pomerantz LLP is investigating potential claims on behalf of ZVRA investors. Although no allegations or findings were detailed, the announcement introduces legal and reputational overhang. Pomerantz investor investigation

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on ZVRA shares. UBS Group restated a “buy” rating on shares of Zevra Therapeutics in a research note on Wednesday, June 24th. Cantor Fitzgerald increased their price target on Zevra Therapeutics from $24.00 to $34.00 and gave the company an “overweight” rating in a research note on Monday, June 8th. Citigroup reissued an “outperform” rating on shares of Zevra Therapeutics in a report on Thursday. Weiss Ratings lowered Zevra Therapeutics from a “buy (b-)” rating to a “hold (c)” rating in a research note on Friday, May 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $26.00 price objective on shares of Zevra Therapeutics in a research report on Tuesday, June 23rd. Nine equities research analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $27.14.

Zevra Therapeutics Price Performance

Shares of ZVRA stock opened at $11.56 on Monday. The business has a fifty day moving average of $12.32 and a 200 day moving average of $10.59. Zevra Therapeutics, Inc. has a 1 year low of $7.16 and a 1 year high of $15.03. The firm has a market capitalization of $686.43 million, a price-to-earnings ratio of 12.57 and a beta of 0.91.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.25 earnings per share for the quarter, beating the consensus estimate of $0.11 by $0.14. The business had revenue of $39.66 million for the quarter, compared to the consensus estimate of $33.88 million. Zevra Therapeutics had a return on equity of 54.54% and a net margin of 42.82%. As a group, equities research analysts expect that Zevra Therapeutics, Inc. will post 0.6 earnings per share for the current year.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome.